SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Trial Profile

SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs SL 401 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 13 Dec 2017 Results published in the Stemline Therapeutics Media Release.
    • 13 Dec 2017 According to a Stemline Therapeutics media release, Median overall survival (OS) did not reached in first-line patients and the follow up is ongoing for 12 month OS in Stage 3.
    • 13 Dec 2017 According to a Stemline Therapeutics media release, data from this trial was presented at the American Society of Hematology (ASH) Annual Meeting and Exposition (2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top